GO
Loading...

Bristol-Myers Squibb Co

More

  • Midday Glance: Pharmaceuticals companies Monday, 27 Apr 2015 | 1:50 PM ET

    Baxter International Inc. fell$. 46 or. 6 percent, to $70.68. Bristol-Myers Squibb Co. fell$. 55 or. 8 percent, to $65.25. Eli Lilly& Co. fell$. 61 or. 9 percent, to $70.97.

  • Early Glance: Pharmaceuticals companies Monday, 27 Apr 2015 | 11:25 AM ET

    Baxter International Inc. rose$. 15 or. 2 percent, to $71.29. Bristol-Myers Squibb Co. rose$. 16 or. 2 percent, to $65.96. Eli Lilly& Co. rose$. 09 or. 1 percent, to $71.67.

  • *FDA cites concerns over late-stage study design, results. April 27- U.S. Food and Drug Administration staff reviewers said an accelerated review of drugmaker Amgen Inc's skin cancer immunotherapy cannot be considered at this time, citing concerns over the design and results of a key study. T-Vec represents a new class of agent for the treatment of metastatic...

  • April 27- Drug developer Celladon Corp said it expected to announce lay-offs and cost cuts as its stock plunged to an all-time low after the company's lead experimental gene therapy to treat heart failure failed a key trial. Celladon lost nearly 80 percent of its market value in early trading on Monday, with the stock falling to a record low of $2.76.

  • *Celladon trial failure shows field remains high-risk. LONDON, April 27- GlaxoSmithKline is close to seeking European approval for a gene therapy drug to fight the immune deficiency disorder known as "bubble boy" disease, in the latest sign of a renaissance in the technology to fix faulty genes. Gene therapy last year won $3.0 billion of financing, up 510 percent on...

  • April 25- Bristol-Myers Squibb Co said its experimental drug cured hepatitis C in over 90 percent of patients in combination with Gilead Sciences Inc's Sovaldi and a commonly prescribed drug, ribavirin, in a late-stage study. Bristol-Myers has been testing the drug, daclatasvir, in combination with Sovaldi after shelving plans to market another hepatitis C...

  • Final Glance: Pharmaceuticals companies Friday, 24 Apr 2015 | 8:08 PM ET

    Baxter International Inc. fell$. 37 or. 5 percent, to $71.14. Bristol-Myers Squibb Co. fell$. 20 or. 3 percent, to $65.80. Eli Lilly& Co. fell$. 82 or 1.1 percent, to $71.58.

  • NEW YORK, April 24- Healthcare companies on a seven-year tear have been top performers so far in 2015, helping to push broad stock indexes to record levels, but traders are now looking to protect themselves from a selloff as they await major earnings reports in the sector. Companies reporting first-quarter earnings next week include Bristol-Meyers Squibb Co,...

  • Midday Glance: Pharmaceuticals companies Friday, 24 Apr 2015 | 1:36 PM ET

    Baxter International Inc. fell$. 39 or. 5 percent, to $71.12. Bristol-Myers Squibb Co. fell$. 28 or. 4 percent, to $65.72. Eli Lilly& Co. fell$. 98 or 1.4 percent, to $71.42.

  • Early Glance: Pharmaceuticals companies Friday, 24 Apr 2015 | 10:55 AM ET

    Baxter International Inc. fell$. 42 or. 6 percent, to $71.09. Bristol-Myers Squibb Co. fell$. 11 or. 2 percent, to $65.89. Pfizer fell$. 11 or. 3 percent, to $35.25.

  • LONDON, April 24- European regulators have recommended approval of Bristol-Myers Squibb's Opdivo, paving the way for it to become the first of a closely watched group of immune system-boosting cancer medicines to go on sale in Europe. It competes with Merck& Co's Keytruda, which is also on the market in the United States but not in Europe. Although Keytruda is...

  • April 24- European health regulators warned on Friday against using Gilead Sciences Inc's and Bristol-Myers Squibb Co's hepatitis C medicines along with amiodarone, a drug used to regulate the heartbeat of people with heart rhythm disorders. The European Medicines Agency said there is a risk of severe bradycardia, or heart block, when Gilead's drug Harvoni...

  • LONDON, April 24- European regulators have recommended approval of Bristol-Myers Squibb's Opdivo, paving the way for it to become the first of a closely watched group of immune system-boosting cancer medicines to go on sale in Europe. The drug, also known as nivolumab, was given a green light on Friday by the European Medicines Agency for the treatment of...

  • LONDON, April 24- AstraZeneca is getting a $450 million windfall by letting Celgene develop a prized immunotherapy drug for blood cancers but its chief executive insists the deal is about strategy, not cash. Chief Executive Pascal Soriot, however, said he had been looking for a partner in blood cancers since last year and by teaming up with U.S.-based Celgene, a...

  • Final Glance: Pharmaceuticals companies Thursday, 23 Apr 2015 | 6:05 PM ET

    Baxter International Inc. rose $1.13 or 1.6 percent, to $71.51. Bristol-Myers Squibb Co. fell$. 60 or. 9 percent, to $66.00. Eli Lilly& Co. rose$. 10 or. 1 percent, to $72.40.

  • Midday Glance: Pharmaceuticals companies Thursday, 23 Apr 2015 | 1:24 PM ET

    Baxter International Inc. rose $1.67 or 2.4 percent, to $72.05. Bristol-Myers Squibb Co. fell$. 54 or. 8 percent, to $66.06. Eli Lilly& Co. rose$. 25 or. 3 percent, to $72.55.

  • Early Glance: Pharmaceuticals companies Thursday, 23 Apr 2015 | 11:02 AM ET

    Baxter International Inc. rose $1.00 or 1.4 percent, to $71.38. Bristol-Myers Squibb Co. fell$. 63 or. 9 percent, to $65.97. Eli Lilly& Co. fell$. 98 or 1.4 percent, to $71.32.

  • April 23- A unit of AstraZeneca Plc has teamed up with Juno Therapeutics Inc to develop combination treatments that use the body's immune system to kill cancer cells. The partnership between AstraZeneca's research and development arm MedImmune and Juno is the latest collaboration between companies intent on developing a new class of drugs known as...

  • Bang for your buck: Where earnings surprises are Thursday, 23 Apr 2015 | 8:28 AM ET
    Traders on the floor of the New York Stock Exchange.

    Three sectors are seeing the biggest rallies following earnings reports. Where investors should place future bets.

  • Final Glance: Pharmaceuticals companies Wednesday, 22 Apr 2015 | 6:13 PM ET

    Baxter International Inc. rose$. 33 or. 5 percent, to $70.38. Bristol-Myers Squibb Co. fell$. 21 or. 3 percent, to $66.60. Hospira rose$. 04 or percent, to $87.80.